An Increased Monocyte Count Predicts Coronary Artery Spasm in Patients with Resting Chest Pain and Insignificant Coronary Artery Stenosis

Kyeong Ho Yun, M.D., Seok Kyu Oh, M.D., Eun Mi Park, M.D., Hyun Jung Kim, M.D., Sung Hee Shin, M.D., Eun Mi Lee, M.D., Sang Jae Rhee, M.D., Nam Jin Yoo, M.D., Nam-Ho Kim, M.D., Jin-Won Jeong, M.D. and Myung Ho Jeong, M.D.

Division of Cardiovascular Medicine, Wonkwang University School of Medicine, The Institute of Medical Sciences, Iksan, Korea; The Heart Center of Chonnam National University Hospital, Gwangju, Korea

INTRODUCTION

Coronary artery spasm plays an important role in the pathogenesis of a variety of ischemic heart disease, including not only variant angina, but also unstable angina, myocardial infarction and sudden death. Although it is still unclear,
Atherosclerotic change in blood vessels.

A few studies have recently reported that atherosclerotic lesions and elevated levels of biologic markers such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) are observed in the patients with coronary vasospasm, and these biologic markers are involved in the early inflammatory responses\textsuperscript{2, 3).} Other studies have reported that the peripheral monocyte count and the percentage of activated T-lymphocytes are increased in the patients with variant angina\textsuperscript{4, 5).}

It also has been widely accepted that the peripheral leukocyte count or the level of high sensitivity C-reactive protein (hsCRP) are indicators for the atherosclerotic change in the early inflammatory responses\textsuperscript{6).} In this study, we assessed the feasibility using the peripheral leukocyte count and the differential count for diagnosing the patients with vasospastic angina.

**MATERIALS AND METHODS**

Study Population

We retrospectively reviewed the medical records of 144 patients who underwent intracoronary ergonovine provocation testing at Wonkwang University Hospital between January 2002 and December 2004. The intracoronary ergonovine test was performed (1) for patients in which chest pain was noted at rest (2) for those patients whose cardiac attack was relieved by the use of sublingual nitroglycerin and (3) for those patients in whom significant coronary artery diseases (>50% of the luminal diameter of the major coronary arteries) were absent. The exclusion criteria were (1) cases in which acute myocardial infarction was noted within the recent six months (2) those cases in which coronary intervention was performed (3) those cases with other infectious diseases and (4) those cases with hepatic and renal diseases.

Data Collection

Coronary angiography was performed with the patients in a fasting state by the Judkin method following puncture of the femoral artery or via a radial artery approach. No pharmacological therapy except nitrate injection was attempted for at least 72 hour prior to coronary angiography. The severity of coronary atherosclerotic lesions in all the patients were evaluated on at least three projections. Ergonovine provocation testing was performed for the patients in whom significant coronary stenosis was absent, as previously reported\textsuperscript{7, 8).} First, the 12 lead electrocardiogram and arterial pressure were monitored after the carbon electrodes (Fukuda Ltd., Japan) were attached; second, ergonovine in 0.9% saline solution was injected into the right coronary artery at 10 μg/min for 4 min for a maximal dose of 40 μg, and then the ergonovine was injected into the left coronary artery at 16 μg/min for 4 min for a total dose of 64 μg with at least a 5 min interval between each injection; and third, the occurrence of chest pain, the change of the ST segment on the EKG and the development of spasm on coronary angiography were examined. We performed frequent test shots at 30-sec intervals with using contrast media during testing, if possible. Positive results were defined as cases in which more than 99% of the focal spasm was noted on coronary angiography in the presence of typical chest pain or abnormal EKG findings. We assigned the patients with spasm and those without spasm to Groups I and II, respectively.

The coronary arteries were measured each time after the intracoronary administration of nitrate and after the completion of testing. The angiographic characteristics of the coronary atherosclerotic lesions were defined by the Gensini's score\textsuperscript{9).} In this scoring system, a greater reduction of the luminal diameter is assigned a higher score and a proximal lesion in the left anterior descending or the circumflex artery is assigned a higher score than a distal lesion. Significant stenosis was defined as a luminal narrowing of 50% or greater.

After overnight fasting, blood sampling was done to measure the total cholesterol, triglyceride, high density lipoprotein (HDL)-cholesterol, low density lipoprotein (LDL)-cholesterol, lipoprotein (a), the erythrocyte sedimentation rate (ESR) and the high-sensitivity C-reactive protein (hsCRP). A complete blood count (CBC) with a differential count was performed within 24 hours before the coronary angiography. We compared the laboratory data between the two groups.

Statistical Analysis

Statistical analysis was done using dBSTAT for Window (dBSTAT Inc, Seoul, Korea). All the data were expressed as means±standard deviation. Intergroup analysis was done using the independent t-test and the \( \chi^2 \) test. Multivariate analysis was done to determine the factors related to vasospastic angina. A receiver operating characteristics (ROC) curve analysis was done to determine whether a CBC with the differential count would be feasible for making the diagnosis. Statistical significance was set at \( p<0.05 \).

**RESULTS**

In our series, the mean age of patients was 55.1±10.4 and the male–to–female ratio was 79:65. Overall, 72 patients were positive for the intracoronary ergonovine test with a positive rate of 50%. The mean value of Gensini's score was 1.34±2.33.
Table 1. Baseline characteristics

| Characteristic                        | Group I (n=72)          | Group II (n=72)          | p value |
|---------------------------------------|-------------------------|-------------------------|---------|
| Age (years)                           | 55.1±10.44              | 55.3±10.20              | 0.763   |
| Male gender (%)                       | 79 (54.9)               | 25 (34.7)               | <0.001  |
| Presence of provoked spasm (%)        | 72 (50.0)               | 25 (34.7)               | <0.001  |
| Systemic hypertension (%)             | 17 (11.8)               | 17 (23.6)               | 0.302   |
| Diabetes mellitus (%)                 | 10 (6.9)                | 10 (6.9)                | 0.743   |
| Smokers (%)                           | 60 (41.7)               | 43 (59.7)               | <0.001  |
| Previous history of statin therapy (%)| 8 (5.6)                 | 6 (8.3)                 | 0.302   |
| Family history of coronary artery disease (%) | 23 (15.9)     | 6 (8.3)                 | 0.302   |
| Ejection fraction (%)                 | 68.2±10.55              | 68.2±10.55              | 0.143   |
| Gensini score                         | 1.34±2.33               | 1.34±2.33               | 0.143   |

Table 2. Clinical and laboratory findings

| Characteristics | Group I (n=72) | Group II (n=72) | p value |
|-----------------|----------------|----------------|---------|
| Age (years)     | 54.8±10.73     | 55.3±10.20     | 0.763   |
| Males (%)       | 54 (75.0)      | 25 (34.7)      | <0.001  |
| Smokers (%)     | 43 (59.7)      | 17 (23.6)      | <0.001  |
| Hypertension (%)| 11 (15.3)      | 6 (8.3)        | 0.302   |
| Diabetes mellitus (%) | 6 (8.3) | 4 (5.6) | 0.743   |
| WBC (/mm³)      | 7496.4±2622.28 | 6703.2±1768.37 | 0.035   |
| Neutrophil (/mm³) | 4385.6±2052.94 | 3802.6±1480.63 | 0.055   |
| Lymphocyte (/mm³) | 2170.0±914.72  | 2185.9±544.57  | 0.899   |
| Monocyte (/mm³)  | 627.5±270.70   | 426.9±205.76   | <0.001  |
| Eosinophil (/mm³)| 307.89±250.50  | 220.9±242.92   | 0.143   |
| ESR (mm/hr)     | 12.1±15.17     | 10.6±8.64      | 0.675   |
| hsCRP (mg/L)    | 3.5±5.72       | 2.2±2.68       | 0.187   |
| Total cholesterol (mg/dL)             | 184.7±32.04     | 192.4±38.12    | 0.191   |
| Triglyceride (mg/dL)                   | 183.0±134.09    | 167.3±82.02    | 0.398   |
| HDL−cholesterol (mg/dL)                | 48.4±13.66      | 49.47±9.36     | 0.578   |
| LDL−cholesterol (mg/dL)                | 106.9±30.65     | 114.95±41.62   | 0.194   |
| BUN (mg/dL)                              | 15.9±4.64      | 14.7±4.17      | 0.108   |
| Creatinine (mg/dL)                      | 1.0±0.30       | 0.9±0.19      | 0.005   |
| Uric acid (mg/dL)                       | 4.9±1.30       | 5.3±1.76      | 0.623   |
| Gensini score                            | 2.2±2.88       | 0.5±1.03      | <0.001  |

WBC, white blood cell; ESR, erythrocyte sedimentation rate; hsCRP, high-sensitivity C-reactive protein; HDL, high density lipoprotein; LDL, low density lipoprotein; BUN, blood urea nitrogen.
### Table 3. Predictive factors of coronary vasospastic angina according to multivariate analysis

| Variable          | Odds ratio | 95% Confidence interval | \( p \) value |
|-------------------|------------|-------------------------|---------------|
| Male gender       | 3.699      | 0.569-24.061            | 0.171         |
| Smoker            | 0.729      | 0.124-4.309             | 0.728         |
| WBC count         | 0.999      | 0.999-1.001             | 0.634         |
| Neutrophil count  | 1.000      | 0.999-1.001             | 0.616         |
| Monocyte count    | 1.004      | 1.000-2.009             | 0.047         |
| Total cholesterol | 0.995      | 0.975-1.016             | 0.632         |
| hsCRP             | 1.025      | 0.867-1.212             | 0.772         |
| Serum creatinine  | 22.167     | 2.699-1828.746          | 0.169         |
| Gensinis score    | 1.753      | 1.103-2.785             | 0.018         |

WBC, white blood cell; hsCRP, high-sensitivity C-reactive protein.

### Table 4. Adjusted odds ratios for coronary vasospastic angina in the quartiles of the monocyte count

| Variable          | Odds ratio | 95% Confidence interval | \( p \) value |
|-------------------|------------|-------------------------|---------------|
| 1st (<375/mm³)    | 1.000      |                         |               |
| 2nd (376-500/mm³) | 3.423      | 1.228-9.539             | 0.019         |
| 3rd (501-605/mm³) | 8.285      | 2.699-25.428            | <0.001        |
| 4th (≥606/mm³)    | 10.774     | 3.581-32.416            | <0.001        |

*The first quartile was used as a reference group.

DISCUSSION

This clinical study indicates that an increased peripheral monocyte count is an independent factor related to coronary vasospastic angina and it is a predictor of coronary vasospasm in patients with resting angina and insignificant coronary artery stenosis.

Coronary artery spasm has been regarded as an etiologic factor that’s involved in the development of various ischemic heart diseases. Nevertheless, the exact mechanism by which coronary spasm develops remains unclear. To date, many authors have postulated that the irregular activity of the autonomic nervous system (ANS) provokes vasospastic angina; that is, once the ANS is activated, it not only stimulates vascular smooth muscle cells to contract, but it also induces platelets to release serotonin, a powerful coronary vasoconstrictor\(^{10}\). In association with this, Miwa et al. reported that the activation of the sympathetic nervous system might be one of the crucial factors affecting coronary vasospasm\(^{11}\). Yoshio et al. and Kim et al. both conducted spectral analysis on the heart rate variability has measured by 24 hours ambulatory Holter monitoring. According to these authors, the power spectral density of the low frequency component was increased before the onset of cardiac attack. This indicates that activation of the sympathetic nervous system might play a crucial role in the development of vasospasm\(^{12, 13}\).

According to most recent evidence, arterial hypercontractility might be the most common anomaly that causes the atherosclerotic changes. Both animal and clinical studies have supported the presence of cellular events (e.g., endothelial...
injury) in the atherosclerotic changes. Besides this, adhesion molecules and leukotrienes are released by platelets and macrophages during the cellular events. Patients with coronary spasm exhibit endothelial dysfunction as well as local hyperreactivity of the coronary arteries. According to Miwa et al., the plasma concentrations of soluble E-selectin and intercellular adhesion molecule-1 were elevated in the patients with variant angina. This is suggestive of an association between the inflammatory responses and coronary spasm. Terashima et al. reported that the chronic activation of T-lymphocytes, and CD8+ T-lymphocytes in particular, was associated with the development of coronary spasm. This implies that the systemic immune and inflammatory responses play a crucial role in the development of coronary spasm. More directly, Hong et al. have maintained that atherosclerotic changes were seen via intravascular ultrasound in all the patients with coronary spasm. The present study has shown that Gensini's score was significantly higher in the patients with spasm, which is similar to the results of these study. Further, intractable spasm can develop in the underlying atherosclerotic lesions.

Several clinical studies have shown the total WBC and monocyte counts to be independent risk factors for coronary heart disease due to atherosclerosis. Especially, monocytes are present in all stages of atherosclerosis: they potentiate inflammatory responses during early plaque development and initiate breakdown and rupture of the fibrous cap. Based on the above results, it can be inferred that an increased monocyte count is an indicator for the early atherosclerotic changes in the patients who are suspected of having vasospastic angina. Presumably, the various chemokines released from the spastic coronary artery might be related to an increased monocyte count. The present study has shown that the monocyte count was positively correlated with Gensini's score. This leads to the speculation that an increased monocyte count indicates the initiation or progression of atherosclerotic changes in patients with vasospastic angina. Further, the increased monocyte count can be acceptable as an important indicator for vasospastic angina in the patients with normal coronary angiography and who are suspected of having coronary vasospasm, which was demonstrated in the present study.

Our results showed that the CRP was not elevated in our subjects, although CRP has been well documented as a marker for the early inflammatory responses. Accordingly, CRP was not associated with coronary vasospasm, which is in agreement with the previous results.

There are several limitations of this study. We retrospectively analyzed the data, and we examined only a small number of patients. Therefore a prospective study that includes a large number of patients may be needed to confirm the results. We suggest here that the monocyte count was a marker for early atherosclerosis; however, we did not compare the monocyte count according to the severity of coronary atherosclerosis. Although our study showed that the monocyte count was positively correlated with Gensini’s score, another study will be needed to confirm our hypothesis.

In conclusion, vasospastic angina is closely related to early atherosclerotic change, and the peripheral monocyte count is a more reliable predictor for vasospastic angina than the other inflammatory markers such as hsCRP. Our results indicate that the peripheral monocyte count is a clinically feasible marker for predicting vasospastic angina in the patients with resting chest pain and angiographically insignificant coronary artery stenosis. However, a prospective clinical study should be conducted to confirm our findings.

REFERENCES

1) Hillis LD, Braunwald E. Coronary-artery spasm. N Engl J Med 299:696-702, 1978
2) Suzuki H, Kawai S, Aizawa T, Kato K, Sunayama S, Okada R, Yamaguchi H. Histologic evaluation of coronary plaque in patients with variant angina: relationship between vasospasm and neointimal hyperplasia in primary coronary lesions. J Am Coll Cardiol 33:198-205, 1999
3) Miwa K, Igarawa A, Inoue H. Soluble E-selectin. ICAM-1 and VCAM-1 levels in systemic and coronary circulation in patients with variant angina. Cardiovasc Res 36:37-44, 1997
4) Terashima M, Akita H, Kanazawa K, Shiga N, Matsuura Y, Hirata K, Kawashima S, Yokoyama M. Circulating T-lymphocyte activation in patients with variant angina. Coron Artery Dis 13:161-168, 2002
5) Hung MU, Kuo LT, Cheng CW, Chang CP, Cheng WJ. Comparison of peripheral monocyte counts in patients with and without coronary spasm and without fixed coronary narrowing. Am J Cardiol 93:620-624, 2004
6) Iitaka J, Wakisatsuki T, Oishi Y, Oki T, Ito S. Leukocyte counts and concentration of soluble adhesion molecules as predictors of coronary atherosclerosis. Coron Artery Dis 11:445-449, 2000
7) Igarashi Y, Yamazoe M, Shibata A. Effect of direct intra coronary administration of methyleugenovine in patients with and without variant angina. Am Heart J 121:1094-1100, 1991
8) Sueda S, Kohno H, Fukuda H, Ochi N, Kawada H, Hayashi Y, Uraoka T. Clinical impact of selective spasm provocation tests: comparisons between acetylcholine and ergonovine in 1508 examinations. Coron Artery Dis 15:491-497, 2004
9) Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 51:636, 1983
10) Miwa K, Toda N. Regional differences in the response to vasoconstrictor agents of dog and monkey isolated coronary arteries. Br J Pharmacol 82:295-301, 1984
11) Miwa K, Igarawa A, Miyagi Y, Nakagawa K, Inoue H. Alterations of autonomic nervous activity preceding nocturnal variant angina: sympathetic augmentation with parasympathetic impairment. Am Heart
12) Yoshio H, Shimizu M, Sughara N, Kita Y, Shimizu K, Minagawa F, Nakabayashi H, Takeda R. Assessment of autonomic nervous activity by heart rate spectral analysis in patients with variant angina. Am Heart J 125:324-329, 1993

13) Kim NH, Jeong JW, Park EM, Yun KH, Yoo NJ, Lee EM, Oh SK, Park OK. Alterations of autonomic nervous activity associated with spontaneous coronary spasm in patients with variant angina. Korean Circ J 34:362-367, 2004

14) Shimokawa H, Ito A, Fukumoto Y, Kadokami T, Nakaike R, Sakata M, Takayanagi T, Egashira K, Takeshita A. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pig in vivo: the role of platelet-derived growth factor. J Clin Invest 97:769-776, 1996

15) Ogawa H, Sakamoto T, Nishiyama K, Soejima H, Kaikita K, Takazoe K, Miyamoto S, Kugiyama K, Yoshimura M, Yasue H. Elevated levels of soluble intercellular adhesion molecule-1 in the coronary circulation of patients with coronary organic stenosis and spasm. Jpn Circ J 64:170-178, 2000

16) Teragawa H, Kato M, Kurokawa J, Yamagata T, Matsuura H, Chayama K. Endothelial dysfunction is an independent factor responsible for vasospastic angina. Clin Sci 101:707-713, 2001

17) Kawano H, Ogawa H. Endothelial function and coronary spastic angina. Intern Med 44:91-99, 2005

18) Hong MK, Park SW, Lee CW, Ko JY, Kang DH, Song JK, Kim JJ, Mintz GS, Park SJ. Intravascular ultrasound findings of negative arterial remodeling at sites of focal coronary spasm in patients with vasospastic angina. Am Heart J 140:395-401, 2000

19) Jeong MH, Park JC, Rhew JY, Kang KT, Lee SH, Cho JH, Kim NH, Kim KH, Ahn YK, Bae Y, Cho JG, Park JC, Kim SH, Kang JC. Successful management of intractable coronary spasm with a coronary stent. Jpn Circ J 64:897-900, 2000

20) Olivares R, Ducimetiere P, Claude JR. Monocyte count: a risk factor for coronary heart disease? Am J Epidemiol 137:49-53, 1993

21) Lee CD, Folsom AR, Nieto FJ, Chambless LE, Shahar E, Wolfe DA. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and White men and women: atherosclerosis risk in communities study. Am J Epidemiol 154:758-764, 2001

22) Weijenberg MP, Feskens EJ, Kromhout D. White blood cell count and the risk of coronary heart disease and all-cause mortality in elderly men. Atheroscler Thromb Vasc Biol 16:499-503, 1996

23) Barron HV, Haar SD, Radford MJ, Wang Y, Krumholz HM. The association between white blood cell count and acute myocardial infarction mortality in patients =65 years of age: findings from the cooperative cardiovascular project. J Am Coll Cardiol 38:1654-1661, 2001

24) Hung MJ, Cheng WJ. Comparison of white blood cell counts in acute myocardial infarction patients with significant versus insignificant coronary artery disease. Am J Cardiol 91:1339-1342, 2003

25) Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126, 1999

26) Buffon A, Biasucci LM, Liuzzo G, D’Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 347:5-12, 2002